NCT05023655 2026-03-17
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
Phase 2 Terminated
Prisma Health-Upstate
Nuvation Bio Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Memorial Sloan Kettering Cancer Center
Gilead Sciences
Debiopharm International SA
Dana-Farber Cancer Institute
Secretaria de Estado da Saúde
Pfizer